Skip to main content

ALSUntangled 38: L-serine.

Publication ,  Journal Article
ALSUntangled Group,
Published in: Amyotroph Lateral Scler Frontotemporal Degener
February 2017

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Amyotroph Lateral Scler Frontotemporal Degener

DOI

EISSN

2167-9223

Publication Date

February 2017

Volume

18

Issue

1-2

Start / End Page

148 / 151

Location

England

Related Subject Headings

  • Treatment Outcome
  • Serine
  • Risk
  • Humans
  • Clinical Trials as Topic
  • Amyotrophic Lateral Sclerosis
  • 3209 Neurosciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
ALSUntangled Group, . (2017). ALSUntangled 38: L-serine. Amyotroph Lateral Scler Frontotemporal Degener, 18(1–2), 148–151. https://doi.org/10.1080/21678421.2016.1250353
ALSUntangled Group, Hiroshi. “ALSUntangled 38: L-serine.Amyotroph Lateral Scler Frontotemporal Degener 18, no. 1–2 (February 2017): 148–51. https://doi.org/10.1080/21678421.2016.1250353.
ALSUntangled Group. ALSUntangled 38: L-serine. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1–2):148–51.
ALSUntangled Group, Hiroshi. “ALSUntangled 38: L-serine.Amyotroph Lateral Scler Frontotemporal Degener, vol. 18, no. 1–2, Feb. 2017, pp. 148–51. Pubmed, doi:10.1080/21678421.2016.1250353.
ALSUntangled Group. ALSUntangled 38: L-serine. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1–2):148–151.

Published In

Amyotroph Lateral Scler Frontotemporal Degener

DOI

EISSN

2167-9223

Publication Date

February 2017

Volume

18

Issue

1-2

Start / End Page

148 / 151

Location

England

Related Subject Headings

  • Treatment Outcome
  • Serine
  • Risk
  • Humans
  • Clinical Trials as Topic
  • Amyotrophic Lateral Sclerosis
  • 3209 Neurosciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences